anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Patients will receive the vaccine monthly (+/- 3 days) for 6 doses as a priming phase followed by booster injections quarterly Q3mo thereafter. If sufficient quantities of vaccine are available, vaccination may continue until development of intolerance or disease progression in the case of fatal high grade neoplasms or for up to one year. Additionally, patients with non-fatal tumors who complete one year of vaccinations and have stable disease at the completion of treatment will be given the option of resuming vaccinations if they develop subsequent progression.
Policy engagement is an essential component of implementation research for scaling up interventions targeting non-communicable diseases (NCDs). It refers to the many ways that research team members, implementers and policymakers, who represent government decision-making, connect and interact to explore common interests. Well-conducted engagement activities foster co-production, local contextualization and assist in the successful translation of research evidence into policy and practice. We aimed to identify the challenges and facilitators to policy engagement during the early implementation phase of scale-up research studies. This qualitative study was focused on the research projects that were funded through the Global Alliance for Chronic Diseases in the 2019 round. Nineteen project teams opted to participate, with these studies implemented in 20 countries. Forty-three semi-structured stakeholder interviews, representing research, implementation and government were undertaken between August 2020 and July 2021. Transcripts were open-coded using thematic analysis to extract 63 codes which generated 15 themes reflecting both challenges and facilitators to undertaking policy engagement. Knowledge of the local government structures and trusting relationships provided the foundation for successful engagement and were strengthened by the research. Four cross-cutting concepts for engagement were identified and included: (1) the importance of understanding the policy landscape; (2) facilitating a network of suitable policy champions, (3) providing an environment for policy leaders to genuinely contribute to co-creation and (4) promoting two-way learning during researcher-policymaker engagement. We recommend undertaking formative policy analysis to gain a strategic understanding of the policy landscape and develop targeted engagement plans. Through engagement, researchers must facilitate cohesive vision and build a team of policy champions to advocate NCD research within their networks and spheres of influence. Ensuring equitable partnerships is essential for enabling local ownership and leadership. Further, engagement efforts must create a synergistic policymaker-researcher lens to promote the uptake of evidence into policy.
The ESPB requires ultrasound guidance which enables visible local anesthetic spread underneath the erector spinae muscles. The spinalis, longissimus thoracis, and iliocostalis muscles comprise the ES muscles, which run vertically along both sides of the vertebral column from the sacrum up to the skull base. The ESPB can be performed in the cervical, thoracic, and lumbar regions. Among them, upper or mid thoracic ESPB has been used more widely compared to cervical and lumbar regions. Previous cadaveric studies on the ESPB at the T5 level using computed tomography (CT) reconstruction or direct dissection demonstrated the extensive craniocaudal distribution of methylene blue ranging from T1 to T8 vertebral segments deep to the ES muscles and variable involvement of epidural, paravertebral, and intercostal spaces. The ESPB performed at the T2 level of the cadaver demonstrated an injected dye distribution ranging from C4 to T10. Also, 36% of cadavers showed the spread of an injected dye to the ventral, dorsal ramus, paravertebral space, and even the contralateral side. The exact mechanism of action of ESPB remains unclear. A recent study suggested that the analgesic effect of ESPB could be obtained by blocking the ventral and dorsal ramus of the spinal nerves by passing through the costotransverse foramen. However, in clinical practice, we can encounter highly variable clinical outcomes or sensory block after the ESPB. The study of the physical spread of the injected agent can be used to predict the clinical result and elucidate the possible mechanism of action of ESPB.
Colonoscopy is the choice procedure to diagnose, screening, and treat the colon and rectum cancer, from early detection of small precancerous lesions (polyps), to confirmation of malign masses. However, the high variability of the organ appearance and the complex shape of both the colon wall and structures of interest make this exploration difficult. Learned visuospatial and perceptual abilities mitigate technical limitations in clinical practice by proper estimation of the intestinal depth. This work introduces a novel methodology to estimate colon depth maps in single frames from monocular colonoscopy videos. The generated depth map is inferred from the shading variation of the colon wall with respect to the light source, as learned from a realistic synthetic database. Briefly, a classic convolutional neural network architecture is trained from scratch to estimate the depth map, improving sharp depth estimations in haustral folds and polyps by a custom loss function that minimizes the estimation error in edges and curvatures. The network was trained by a custom synthetic colonoscopy database herein constructed and released, composed of 248400 frames (47 videos), with depth annotations at the level of pixels. This collection comprehends 5 subsets of videos with progressively higher levels of visual complexity. Evaluation of the depth estimation with the synthetic database reached a threshold accuracy of 95.65%, and a mean-RMSE of 0.451cm, while a qualitative assessment with a real database showed consistent depth estimations, visually evaluated by the expert gastroenterologist coauthoring this paper. Finally, the method achieved competitive performance with respect to another state-of-the-art method using a public synthetic database and comparable results in a set of images with other five state-of-the-art methods. Additionally, three-dimensional reconstructions demonstrated useful approximations of the gastrointestinal tract geometry. Code for reproducing the reported results and the dataset are available at https://github.com/Cimalab-unal/ColonDepthEstimation.
Neuroinflammation plays an important role in the pathogenesis of neurodegenerative diseases, and interrupting the microglial-mediated neuroinflammation has been suggested as a promising strategy to delay or prevent the progression of neurodegeneration. In this study, we investigated the effects of JE-133, an optically active isochroman-2H-chromene conjugate containing a 1,3-disubstituted isochroman unit, on lipopolysaccharide (LPS)-induced microglial neuroinflammation and underlying mechanisms both in vitro and in vivo. First, JE-133 treatment decreased LPS-induced overproduction of interleukin-1 beta (IL-1β), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), nitrite, and nitric oxide synthase (iNOS) in BV2 microglial cells. Further study revealed that JE-133 downregulated the phosphorylation level of JAK/STAT and upregulated the protein level of Nrf2/HO-1 in LPS-stimulated BV2 microglial cells and verified that JE-133 directly bound to Keap1 by a pull-down assay. Next, JE-133 administration also inhibited neuroinflammation in vivo, as indicated by a reduced CD11b protein level and an overexpressed mRNA level of the pro-inflammatory cytokine TNF-α in the hippocampus of LPS-injected mice. Moreover, the regulative effects of JE-133 on the JAK/STAT and Nrf2/HO-1 pathways were also verified in the hippocampus of LPS-injected mice. Taken together, our study for the first time reports that JE-133 exhibits inhibitory effects against LPS-stimulated neuroinflammation both in vitro and in vivo, which might be associated with the simultaneous regulation of the JAK/STAT and Nrf2 pathways. Our findings may provide important clues for the discovery of effective drug leads/candidates against neuroinflammation-associated neurodegeneration.
PURPOSE OF REVIEW: Measurable residual disease (MRD) is integral in the management of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL). This review discusses the current methods used to evaluate MRD as well as the interpretation, significance, and incorporation of MRD in current practice.
RECENT FINDINGS: New molecular technologies have allowed the detection of MRD to levels as low as 10- 6. The most used techniques to evaluate MRD are multiparametric flow cytometry (MFC), quantitative reverse transcription polymerase chain reaction (RT-qPCR), and high-throughput next-generation sequencing (NGS). Each method varies in terms of advantages, disadvantages, and MRD sensitivity. MRD negativity after induction treatment and after allogeneic hematopoietic cell transplantation (HCT) is an important prognostic marker that has consistently been shown to be associated with improved outcomes. Blinatumomab, a new targeted therapy for Ph + ALL, demonstrates high efficacy in eradicating MRD and improving patient outcomes. In the relapsed/refractory setting, the use of inotuzumab ozogamicin and tisagenlecleucel has shown promise in eradicating MRD. The presence of MRD has become an important predictive measure in Ph + ALL. Current studies evaluate the use of MRD in treatment decisions, especially in expanding therapeutic options for Ph + ALL, including tyrosine kinase inhibitors, targeted antibody therapies, chimeric antigen receptor cell therapy, and HCT.
Participants will receive ALXN1820 SC or ALXN1820 IV according to their assigned cohort. ALXN1820 SC will be evaluated in single and multiple ascending doses while ALXN1820 IV will be evaluated in a single dose cohort only.
The current International Society for Heart and Lung Transplantation (ISHLT) guidelines provide a class I recommendation for tachy-therapy re-activation in patients with ICDs undergoing LVAD implantation. However, these guidelines reflect a survival benefit observed in cohorts comprised primarily of older-generation pulsatile flow LVADs. While the overall VA prevalence in the LVAD population exceeds 50% with VA usually occurring \>200 beats per minute, VA are generally well-tolerated both hemodynamically and symptomatically. Observed LVAD flows do decrease during sustained VA but there are multiple case reports of LVAD patients remaining awake and asymptomatic despite hours of ventricular fibrillation and a large case series reported no deaths and rare syncope due to VA in CF LVAD patients. Contrary to guidelines, contemporary evaluations restricted to CF LVADs show no clear ICD survival benefit in single center studies nor a large, pooled meta-analysis. In fact, propensity-matched analyses of CF LVAD patients in the INTERMACS and UNOS registries have demonstrated increased mortality and more hospitalizations among patients with an active ICD and treated VA. It is unclear in the CF LVAD population whether ICD shocks themselves are harmful or rather identify a higher-acuity patient subgroup. In the general HF population, however, shocks have consistently been associated with worse outcomes. Shock reduction programming resulted in reduced mortality in the MADIT-RIT trial, suggesting shocks may be directly harmful and not only a marker of substrate.

Therefore, the present study will evaluate whether ultra-conservative (UC) programming for ICDs can reduce shocks over standard (physician-discretion) programming among patients with heart failure on CF LVAD support. The model is 1:1 randomization between the two programming strategies for patients with newly implanted CF LVAD devices and a pre-existing ICD. They will be eligible for enrollment during their index hospitalization, and after discharge up to their first outpatient follow-up visit no later than 3 months post discharge. The primary endpoints will be any ICD shock, all-cause mortality, and syncope. The secondary endpoints will be time to first ICD shock, time to first ICD shock for VT/VF, quality of life questionnaire and hospitalizations, including for heart failure and ventricular arrhythmias. The principal exclusion criteria will be pediatric patients, or those without a functional ICD system. Standard of care follow-up will continue thru 24 months.
Solid tumors as well as leukemias and lymphomas show striking changes in nuclear structure including nuclear size and shape, the number and size of nucleoli, and chromatin texture. These alterations have been used in cancer diagnosis and might be related to the altered functional properties of cancer cells. The nuclear matrix (NM) represents the structural composition of the nucleus and consists of nuclear lamins and pore complexes, an internal ribonucleic protein network, and residual nucleoli. In the nuclear microenvironment, the NM is associated with multi-protein complexes, such as basal transcription factors, signaling proteins, histone-modifying factors, and chromatin remodeling machinery directly or indirectly through scaffolding proteins. Therefore, alterations in the composition of NM could result in altered DNA topology and changes in the interaction of various genes, which could then participate in a cascade of the cancer process. Using an androgen-sensitive prostate cancer cell line, LNCaP, and its androgen-independent derivative, LN96, conventional 2D-proteomic analysis of the NM proteins revealed that purine-rich element binding protein alpha (PURα) was detected in the NM proteins and differentially expressed between the cell lines. In this article, we will review the potential role of the molecule in prostate cancer.
PROBLEM TO BE SOLVED: To obtain an extremely strong platelet coagulation inhibiting material, having good thermal stability by compounding an extract of a food widely available in Japan as an active component. SOLUTION: NATTOU (fermented soybean) or a cultured liquid of Bacillus natto is extracted singly with water or with an extracting liquid prepared by combining water with an alcohol or several kinds of salts. The obtained material can be used as an active component as it is. Further, the obtained material is optionally purified by adequately carrying out a polar organic solvent treatment, salting-out and ultrafiltration and subsequently further performing purification operation of one or more kinds selected from absorption, ion-exchange chromatography, gel filtration, affinity chromatography, etc. The obtained platelet coagulation-inhibiting material is effective for treating or prophylaxis of circulatory failure attributable to thrombus formation in a blood vessel.  Further, the raw material is derived from a food, and accordingly the platelet coagulation-inhibiting material is excellent in safety.
It is found that a knockout mouse having a lost S1-5 gene function can induce an aging-related disease or condition. In the knockout mouse, it is found that the bone mineral content, the bone density and the bone strength are reduced and that the number of osteoclasts in the bone tissue is increased. As a result of the analysis on the ability to form osteoclasts using bone marrow cells derived from the knockout mouse, it is found that the knockout mouse is increased in the ability to form osteoclasts and also is increased in size of osteoclasts compared to a wild-type mouse. When purified S1-5 protein is added to the in vitro system, it is found that the ability to form osteoclasts is reduced. Further, when purified S1-5 protein is administered to an osteoporosis model mouse, it is found that the S1-5 protein can ameliorate osteoporosis. These findings indicate that S1-5 protein is useful for the treatment or prevention of an aging-related disease such as osteoporosis.
The present invention provides a heat-not-burn (HNB) cartridge structure, comprising a cartridge packaging housing and HNB tobacco particles contained therein. The cartridge packaging housing is composed of a cartridge cup, a cover film and sealing films. The cartridge cup is provided with a top opening and a bottom end face; the cover film and the bottom end face are provided with gas circulating holes; the top opening is sealed by the cover film; the cover film and the bottom end face are sealed with the sealing films at the outer surface. An absorbent cotton is arranged at the bottom end face in the cartridge cup. A body of the cartridge cup has a taper. The cross section of the cartridge cup can be round, oval, quadrilateral, polygonal or irregular-shaped. The cartridge structure of the present invention is applicable to a wide array of HNB heating smoking sets, delivering a better compatibility between a cartridge and a heating cavity of each smoking set as well as a higher air tightness therebetween, thus remarkably improving the heating and suction effects of the cartridge.
<P>PROBLEM TO BE SOLVED: To provide a sunscreen cosmetic that has excellent UVB and UVA-defensive property and gives good using sense, causes no deposition of crystals with the passage of time.  <P>SOLUTION: This sunscreen cosmetic preferably comprises modified titanium oxide prepared by hydrophobic surface-treating a substantially aluminum-free titanium oxide with silica and a dibenzoilmethane compound. In this modified titanium oxide, the total amount of the surface covering is preferably is 1 to 20 mass% based on the titanium. The titanium oxide is preferably the rutile type. The dibenzoilmethane compound is suitably 4-tert.-butyl-4'-methoxydibenzoilmethane. This cosmetic preferably contains a long-chain alkyl-including modified organopolysiloxane, in addition.  <P>COPYRIGHT: (C)2007,JPO&INPIT
Apply medium-intensity ultrasound to the participant. The intensity is below 5 W/cm².
SmofKabiven emulsion for infusion will be continuously infused intravenously via central venous access for approximately 14-24 h/d. Duration of treatment with the study drug is 5 consecutive days.Targeted daily dose is 26.3 ml/kg bw/day resulting in 29.3 kcal/kg bw/day. Dosage on D 1 will be reduced to 50%.
The invention relates to a compound fermented aweto capsule and a preparation method thereof. The compound fermented aweto capsule is prepared by mixing fermented aweto fungus powder, fermented ganoderma lucidum fungus powder and magnesium stearate. The formula (by weight) of the compound fermented aweto capsule is as follows: the fermented aweto fungus powder accounts for 46-86%, the fermented ganoderma lucidum fungus powder accounts for 53.2-13.2%, the magnesium stearate accounts for 0.8%, the fermented aweto fungus powder, the fermented ganoderma lucidum fungus powder and the magnesium stearate are combined to prepare the compound fermented aweto capsule, and each capsule is 0.5g. Ganoderan (calculated by glucan) in the fermented ganoderma lucidum fungus powder is not less than 2.54g/100g; total triterpene (calculated by ursolic acid) is not less than 2.64g/100g. The content of adenosine in the fermented aweto fungus powder is not less than 180mg/100g. The invention is suitable for preparing and producing the compound fermented aweto capsule.
Method of labelling organic substances contg. >=2 vicinal OH gps. or >=1 enolic OH gp. (esp. cell metabolites) with radioactive Tc comprises contacting the organic substance with a radioactive Tc cpd. and a reducing agent having a standard potential of O V in an alkaline soln. or alkaline buffer with a pH of 11-12. After the reaction, the soln. is adjusted to physiological pH by adding a physiologically tolerable acid or buffer. Method can be used to label alcohols, sugars, nucleosides, polysaccharides, hydroxylated fatty acids, and various drugs, etc., for medical or biochemical scintigraphic and/or autoradiographic investigations. High yields (90-99%) of the labelled substance can be obtd.
This is a prospective, multicenter, open-label Phase 3 study of a microbiota suspension of intestinal microbes. The primary assessments for this study are (i) safety via assessment of treatment-emergent adverse events and (ii) efficacy of RBX2660 preventing recurrent episodes of CDI measured at 8 weeks after treatment. Follow-up office visits occur at 1 week and 8 weeks after completing the initial study treatment. Telephone assessments occur at 4 weeks, and 4 and 6 months after the study. Patients who have had at least one recurrence of CDI after a primary episode and have completed at least one round of standard-of-care oral antibiotic therapy or have had at least two episodes of severe CDI resulting in hospitalization may be eligible for the study. Subjects may receive a second RBX2660 enema if they are deemed treatment failures following the initial enema per the protocol-specified treatment failure definition.
The principles of our invention can be applied to both push-saws and pull-saws. More points could, of course, be used. A change in the pitch changes the ratio between forces applied parallel and perpendicular to the stroke direction, and therefore determines how aggressive the saw will behave. For hard stock, a less aggressive behavior is more efficient, decreasing the forces applied perpendicular to the stroke direction. For soft stock, a more aggressive behavior is more efficient, increasing the forces applied perpendicular to the stroke direction and decreasing the number of strokes necessary to cut through a particular piece of stock. Furthermore, the preferred embodiment of our invention allows multiple saw blades to be used with each saw for cutting a variety of materials (wood, metal, plastics, etc.).
PURPOSE: Provided are a method for extracting polysaccharide from Bletilla striata Reichb. fil., the use of the extracted polysaccharide for moisturization, injury curing and cell proliferation, and a cosmetic composition containing the extracted polysaccharides. CONSTITUTION: A method for extracting polysaccharide from Bletilla striata Reichb. fil. comprises the steps of: drying and finely cutting Bletilla striata Reichb. fil., adding an extraction solvent thereto, based on the dried weight; heating them at 30-70 deg.C for 4-48 hours or dipping them at 5-37 deg.C for 1-15 days; and filtering solids and drying them.
Families receive benefits (cash) in exchange for state-sanctioned flexible labour within close proximity (2 km) to household. Eligible for variation of minimum graduation package benefits, such as asset transfer, financial literacy, skills training, sensitizations.
The complexity of sensorimotor control required for hand function as well as the wide range of recovery of manipulative abilities makes rehabilitation of the hand most challenging. The investigators past work has shown that training in a virtual environment (VE) using repetitive, adaptive algorithms has the potential to be an effective rehabilitation medium to facilitate motor recovery of hand function. These findings are in accordance with current neuroscience literature in animals and motor control literature in humans. The investigators are now in a position to refine and optimize elements of the training paradigms to enhance neuroplasticity. The investigators first aim tests if and how competition among body parts for neural representations stifles functional gains from different types of training regimens. The second aim tests the functional benefits of unilateral versus bilateral training regimens.The third aim tests whether functional improvements gained from training in a virtual environment transfer to other (untrained) skills in the real world.